Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial

Author:

Jerusalem Guy,Delea Thomas E.ORCID,Martin Migule,De Laurentiis MichelinoORCID,Nusch Arnd,Beck J. Thaddeus,Chan ArleneORCID,Im Seock-Ah,Neven Patrick,Lonshteyn Alexander,Chandiwana David,Lanoue BradORCID,Fasching Peter A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Canadian Cancer Society. Breast Cancer Statistics. 2019 Available at: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=on. Accessed: February 10, 2019.

2. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: female breast cancer. Natl Cancer Inst 2021. Available at: https://seer.cancer.gov/statfacts/html/breast.html. Accessed: April 16, 2021.

3. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Ann Oncol,2017

4. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline;Partridge;J Clin Oncol,2014

5. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4);Cardoso;Ann Oncol,2018

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3